Corcept Therapeutics Insider Activity and Clinical Data Provide Mixed Signals
Corcept Therapeutics' President, Sean Maduck, executed multiple transactions involving the company's common stock in early June 2026. These sales and acquisitions occurred against a backdrop of strong market performance for CORT. Furthermore, the company recently reported its Q1 2026 earnings and presented positive Phase 3 trial data for Lifyorli, …